Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 8/2022

18-06-2022 | Migraine | Episodic Migraine (S Nahas, Section Editor)

Advocacy for Migraine Relief: Strategic Planning to Eliminate the Burden

Author: Teshamae S. Monteith

Published in: Current Pain and Headache Reports | Issue 8/2022

Login to get access

Abstract

Purpose of Review

The goal of this article is to describe migraine advocacy as an essential means to advance the field of headache medicine. Special attention is spent outlining advocacy initiatives and priorities.

Recent Findings

There is little written about “migraine advocacy” in the literature. However, organizational and expert priorities include advocating for policies that improve systems of care, telemedicine, education, research, and public initiatives that reduce health disparities and the stigma of migraine.

Summary

This summary includes the latest advocacy efforts to support policies that may improve migraine care, strengthen the field of headache medicine, and eliminate the burden of migraine.
Literature
1.
Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, et al. Migraine Nat Rev Dis Primers. 2022;8(1):2.CrossRef
2.
Tepper SJ, Dahlof CG, Dowson A, Newman L, Mansbach H, Jones M, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004;44(9):856–64.CrossRef
3.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.CrossRef
4.
Hubinette M, Dobson S, Scott I, Sherbino J. Health advocacy. Med Teach. 2017;39(2):128–35.CrossRef
5.
Young WB. De-stigmatizing migraine - with words. Headache. 2018;58(2):319–21.CrossRef
6.
Garcia-Albea E. Migraine associated with conversion symptoms (Babinski’s migraine): evaluation of a series of 43 cases. Neurologia. 2012;27(3):125–35.CrossRef
7.
De la Babinski J. migraine ophtalmique hystérique. Archives de Neurologie. 1890;20:305–35.
8.
Jurgens TP, May A. Does the neurobiology of migraine make migraine patients “difficult”? Headache. 2012;52(10):1607–8.CrossRef
9.
10.
Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia. 1996;16(4):231–8; discussion 15.
11.
Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45(Suppl 1):S3–13.CrossRef
12.
Collaborators GBDH. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–76.CrossRef
13.
Coronavirus Resource Center. John Hopkins University of Medicine. 2022.
14.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRef
15.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRef
16.
Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201.
17.
Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, et al. Characterizing Long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722.CrossRef
18.
Huang Y, Pinto MD, Borelli JL, Mehrabadi MA, Abrihim H, Dutt N, et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. medRxiv. 2021.
19.
20.
Janakiram C, Fontelo P, Huser V, Chalmers NI, Lopez Mitnik G, Brow AR, et al. Opioid prescriptions for acute and chronic pain management among Medicaid beneficiaries. Am J Prev Med. 2019;57(3):365–73.CrossRef
21.
Patel UK, Malik P, Shah D, Sharma A, Bhela J, Chauhan B, et al. The opioid epidemic and primary headache disorders: a nationwide population-based study. Cureus. 2020;12(8):e9743.PubMedPubMedCentral
22.
Scher AI, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321–8.CrossRef
23.
Miller J, Koons L, Longyhore D. Opioid free treatment algorithm for ED headache management: effect on revisit rate. Am J Emerg Med. 2020;38(1):28–32.
24.
SERVICES USDOHAH. Strategy to combat opioid abuse, misuse, and overdose. 2018.
25.
26.
Theeler BJ, Mercer R, Erickson JC. Prevalence and impact of migraine among US Army soldiers deployed in support of Operation Iraqi Freedom. Headache. 2008;48(6):876–82.CrossRef
27.
Ailani J, Burch RC, Robbins MS. Board of Directors of the American Headache S. Update on integrating new migraine treatments into clinical practice. Headache: The American Headache Society Consensus Statement; 2021.
28.
Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lanteri-Minet M, Lipton RB, et al. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. Cephalalgia. 2021;41(3):279–93.CrossRef
29.
Newman TV, Munshi KD, Neilson LM, Good CB, Swart ECS, Huang Y, et al. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study. J Manag Care Spec Pharm. 2021;27(4):435–43.PubMed
30.
Shapiro RE, Hochstetler HM, Dennehy EB, Khanna R, Doty EG, Berg PH, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90.CrossRef
31.
Moreno-Ajona D, Perez-Rodriguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309–15.CrossRef
32.
Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470–85.CrossRef
33.
Hatcher-Martin JM, Busis NA, Cohen BH, Wolf RA, Jones EC, Anderson ER, et al. American Academy of Neurology Telehealth Position Statement. Neurology. 2021.
34.
Chiang CC, Halker Singh R, Lalvani N, Shubin Stein K, Henscheid Lorenz D, Lay C, et al. Patient experience of telemedicine for headache care during the COVID-19 pandemic: an American Migraine Foundation survey study. Headache. 2021;61(5):734–9.CrossRef
35.
Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61(1):60–8.CrossRef
36.
Nagata JM, Weiser SD, Gooding HC, Garber AK, Bibbins-Domingo K, Palar K. Association between food insecurity and migraine among US young adults. JAMA Neurol. 2019;76(9):1121–2.CrossRef
37.
To T, Wu K. Health care utilization and disability of migraine: the Ontario Health Survey. Can J Public Health. 1995;86(3):195–9.PubMed
38.
39.
40.
Goadsby PJ. The vascular theory of migraine–a great story wrecked by the facts. Brain. 2009;132(Pt 1):6–7.CrossRef
41.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.CrossRef
42.
Tfelt-Hansen PC, Koehler PJ. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache. 2011;51(5):752–78.CrossRef
43.
Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(Pt 1):232–41.CrossRef
44.
Schulte LH, Jurgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J Headache Pain. 2015;16:14.CrossRef
45.
46.
47.
Tarver ME. Race and ethnicity in real-world data sources: considerations for medical device regulatory efforts. J Prim Care Community Health. 2021;12:2150132721994040.CrossRef
48.
Pace A, Orr SL, Rosen NL, Safdieh JE, Cruz GB, Sprouse-Blum AS. The current state of headache medicine education in the United States and Canada: an observational, survey-based study of neurology clerkship directors and curriculum deans. Headache. 2021;61(6):854–62.CrossRef
49.
Cooper LA, Roter DL, Johnson RL, Ford DE, Steinwachs DM, Powe NR. Patient-centered communication, ratings of care, and concordance of patient and physician race. Ann Intern Med. 2003;139(11):907–15.CrossRef
50.
Wijeratne T, DePold HA. Residency training: advocacy training in neurology: lessons from the Palatucci Advocacy Leadership Forum. Neurology. 2013;80(1):e1-3.CrossRef
51.
Arca KN, Starling AJ. Advocacy in Headache Medicine: Tips at the bedside, the institutional level, and beyond. Curr Neurol Neurosci Rep. 2020;20(11):52.CrossRef
Metadata
Title
Advocacy for Migraine Relief: Strategic Planning to Eliminate the Burden
Author
Teshamae S. Monteith
Publication date
18-06-2022
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 8/2022
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-022-01059-1

Other articles of this Issue 8/2022

Current Pain and Headache Reports 8/2022 Go to the issue

Secondary Headache (M Robbins, Section Editor)

Recent Advances and Future Directions in Middle Meningeal Artery Embolization for Chronic Subdural Hematomas

Neuromodulation (A Abd-Elsayed, Section Editor)

Cervical Spinal Cord Stimulation for Trigeminal Neuralgia: a Narrative Review

Alternative Treatments for Pain Medicine (M Jones, Section Editor)

The Impact of Smoking on the Development and Severity of Chronic Pain

Neuropathic Pain (A Abd-Elsayed, Section Editor)

Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review

Neuromodulation (A Abd-Elsayed, Section Editor)

Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies

Chronic Pain Medicine (O Viswanath, Section Editor)

Challenges in Utilizing Telehealth for Chronic Pain